亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AAPG 亚盛医药

盘后交易 02-04 19:47:17 EST

24.15

+0.82

+3.51%

盘后24.15

+0.000.00%

16:10 EST

最高24.32	最低23.75	成交量1,419
今开23.75	昨收23.33	日振幅2.44%
总市值22.54亿	流通市值17.29亿	总股本9,333万
成交额3.41万	换手率0.00%	流通股本7,158万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":24.15,"timestamp":1770238800000,"preClose":23.33,"halted":0,"volume":1419,"hourTrading":{"tag":"盘后","latestPrice":24.15,"preClose":24.15,"latestTime":"16:10 EST","volume":125,"amount":3018.700125,"timestamp":1770239403948,"change":0,"changeRate":0,"amplitude":0.000414},"delay":0,"changeRate":0.03514787826832406,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"盘后交易","change":0.82,"latestTime":"02-04 19:47:17 EST","open":23.75,"high":24.32,"low":23.75,"amount":34134.137235,"amplitude":0.024432,"askPrice":36,"askSize":100,"bidPrice":23.68,"bidSize":84,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1770253200000},"marketStatusCode":4,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":23.33,"preHourTrading":{"tag":"盘前","latestPrice":24,"preClose":23.33,"latestTime":"09:24 EST","volume":150,"amount":3600,"timestamp":1770215097950,"change":0.67,"changeRate":0.028718,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":24.15,"preClose":24.15,"latestTime":"16:10 EST","volume":125,"amount":3018.700125,"timestamp":1770239403948,"change":0,"changeRate":0,"amplitude":0.000414},"volumeRatio":0.382624},"requestUrl":"/m/hq/s/AAPG","defaultTab":"news","newsList":[{"id":"2608335305","title":"亚盛医药-B盘中涨超3% BTK降解剂1类新药APG-3288片获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2608335305","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608335305?lang=zh_cn&edition=full","pubTime":"2026-02-04 11:08","pubTimestamp":1770174480,"startTime":"0","endTime":"0","summary":"　　亚盛医药-B盘中涨超3%，截至发稿，股价上涨1.38%，报45.88港元，成交额3697.50万港元。公开资料显示，这是亚盛医药研发的新一代BTK靶向蛋白降解疗法。　　APG-3288是亚盛医药自主研发的首个新型高效和高选择性BTK降解剂。临床前研究结果显示，与其他在研BTK降解剂相比，APG-3288具更强的BTK降解能力、更高的选择性及更优越的PK特征，呈现潜力。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-04/doc-inhkrihn3096297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK4129","BK1161","AAPG","BK4139","LU1923622291.USD","APG","LU2125909916.SGD","LU2125909759.SGD","06855"],"gpt_icon":0},{"id":"2603937939","title":"2026年JPM大会诺华、阿斯利康、辉瑞等巨头超百亿美元交易频现，中国资产成最大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937939","media":"药厂那点事儿","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603937939?lang=zh_cn&edition=full","pubTime":"2026-01-16 07:05","pubTimestamp":1768518317,"startTime":"0","endTime":"0","summary":"巨头交易频现，中国资产备受青睐。诺华公司周二下午宣布了一项针对中国生物技术公司泽璟生物的许可交易。再生元计划在2026年公布该药用于肥胖治疗的中国3期临床试验结果，并启动全球3期临床开发计划。截至2025年第三季度，19家大型制药公司现金储备总额超过1700亿美元，2025年前三季度产生了约1400亿美元的自由现金流，为大规模并购交易提供了充足的资金支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","AAPG","02615","02269","06978","ZLAB","09688","06855","02268","BK1161","01530","BK1191","01477","02359"],"gpt_icon":0},{"id":"2601828013","title":"港股异动 | 亚盛医药-B(06855)涨近4% BTK降解剂APG-3288新药临床申请获美国FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828013","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601828013?lang=zh_cn&edition=full","pubTime":"2026-01-07 10:39","pubTimestamp":1767753579,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B(06855)涨近4%，截至发稿，涨3.69%，报53.4港元，成交额6164.18万港元。消息面上，1月7日，亚盛医药官微消息，公司宣布，原创新一代BTK靶向蛋白降解剂 APG-3288的新药临床申请(IND)已获美国FDA许可，将开展其治疗复发/难治B细胞恶性肿瘤的临床研究。这标志着公司在靶向蛋白降解领域的研发成果正式进入临床阶段，是亚盛医药全球创新管线的又一重大布局。该研究是一项全球多中心、开放性的I期临床研究，旨在评估APG-3288治疗复发/难治性血液系统恶性肿瘤患者的安全性、耐受性、PK特征及初步疗效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4129","06855","APG","AAPG","LU2125909759.SGD","BK1574","BK4139","LU2125909916.SGD","BK1161","LU1923622291.USD"],"gpt_icon":0},{"id":"2595713529","title":"亚盛医药-B(06855)：David Sidransky将获委任为首席独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2595713529","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595713529?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:47","pubTimestamp":1767106065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，Debra Yu博士将获委任为董事会提名委员会新增成员，自2025年12月26日起生效。David Sidransky博士将获委任为首席独立非执行董事，自2025年12月26日起生效，以作为其他董事与本公司股东之间的中间人;及在与董事会主席或本公司管理层的正常沟通渠道不足的情况下，可与其他董事及本公司股东联络。研发委员会将由Marc E. Lippman, MD博士担任主席，由David Sidransky博士及王少萌博士担任成员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","BK1574","06855","AAPG"],"gpt_icon":0},{"id":"2592466968","title":"中金:维持亚盛医药-B(06855)“跑赢行业”评级 POLARIS-1欧美获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2592466968","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592466968?lang=zh_cn&edition=full","pubTime":"2025-12-17 11:38","pubTimestamp":1765942705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持亚盛医药-B“跑赢行业”评级与目标价89港元，公司近期研发进展积极。耐立克一线治疗Ph+ ALL的全球III期研究已获欧美药监机构批准开展，并公布亮眼初步数据；利生妥针对高危基线人群亦显示出良好疗效与安全性，整体研发管线持续兑现，国际化稳步推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","06855"],"gpt_icon":0},{"id":"2590316824","title":"【直击2025 ASH】亚盛医药耐立克®二线治疗CML-CP临床研究数据更新，更前线治疗潜力明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316824","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590316824?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:34","pubTimestamp":1765244040,"startTime":"0","endTime":"0","summary":"此次公布是对该研究在2024 ASH年会口头报告结果的持续更新，展现了更长时间的随访疗效与安全性特征。此次更新的研究结果进一步提示耐立克有望为二线CML-CP患者带来一种安全有效的治疗选择，尤其对那些一线使用二代BCR-ABL1酪氨酸激酶抑制剂治疗失败的患者。此次数据的更新，进一步体现了耐立克为更广泛的CML患者群体提供安全有效治疗选择的潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842159_ZH42159_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","06855","LU2463526074.USD","CP","BK4585","LU1261432733.SGD","BK4016","AAPG","ASH","BK4139","BK1161","BK4109","BK4588"],"gpt_icon":0},{"id":"2589519008","title":"港股异动 | 亚盛医药-B(06855)涨超6% 耐立克®POLARIS-1研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589519008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589519008?lang=zh_cn&edition=full","pubTime":"2025-12-05 09:33","pubTimestamp":1764898401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超6%，截至发稿，涨5.67%，报64.2港元，成交额1993.31万港元。消息面上，12月5日，亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。作为耐立克在欧美监管机构获批的第二个全球注册III期研究，POLARIS-1研究在多国家多中心同步入组，将加速耐立克全球特别是欧美市场的上市进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06855","BK4139","BK1161","EMA","BK4081","AAPG"],"gpt_icon":0},{"id":"2589985521","title":"亚盛医药-B(06855)耐立克®一线治疗Ph+ ALL的全球注册III期临床研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589985521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589985521?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:03","pubTimestamp":1764893004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。同时，耐立克在Ph+ ALL领域深度布局，针对Ph+ ALL领域的治疗已获《CSCO恶性血液病诊疗指南》连续推荐，并获CDE突破性疗法认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1699723380.USD","BK1574","BK4585","AAPG","LU0985320562.USD","LU1571399168.USD","BK4107","06855","BK1161","BK4588","EMA","III","BK4134","BK4139","BK4533","ALL","BK4081","LU2355687059.USD"],"gpt_icon":0},{"id":"2586467228","title":"亚盛医药-B(06855)授出130.45万份受限制股份单位及73.66万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2586467228","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586467228?lang=zh_cn&edition=full","pubTime":"2025-11-27 21:18","pubTimestamp":1764249535,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，截至本公告日期，已根据2022年受限制股份单位计划向2022年受限制股份单位计划的146名获选人士授出130.45万份受限制股份单位，相当于130.45万股股份(2022年进一步授出)。截至本公告日期，公司根据首次公开发售后购股权计划条款向34名获授人授出合共73.66万份购股权，可于行使有关购股权时认购合共73.66万股公司普通股，惟须待购股权获授人接纳后方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4139","06855","BK1574","AAPG"],"gpt_icon":0},{"id":"2586284951","title":"港股亚盛医药-B涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586284951","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586284951?lang=zh_cn&edition=full","pubTime":"2025-11-26 11:03","pubTimestamp":1764126180,"startTime":"0","endTime":"0","summary":"每经AI快讯，亚盛医药-B(06855.HK)涨超3%，截至发稿，涨3.04%，报64.35港元，成交额4604.84万港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-11-26/doc-infysxme3338276.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-26/doc-infysxme3338276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK4139","AAPG","BK1574","06855"],"gpt_icon":0},{"id":"2586281468","title":"港股异动 | 亚盛医药-B(06855)涨超3% 首次揭示奥雷巴替尼通过调控脂质代谢发挥抗肿瘤作用全新机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2586281468","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586281468?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:47","pubTimestamp":1764125279,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超3%，截至发稿，涨3.04%，报64.35港元，成交额4604.84万港元。研究结果表明奥雷巴替尼在琥珀酸脱氢酶缺陷型GIST中具有良好的疗效与安全性，并首次揭示奥雷巴替尼通过调控脂质代谢发挥抗肿瘤作用的全新机制。据悉，这是迄今为止针对该罕见GIST亚型规模最大的前瞻性临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1161","06855","BK4139","BK1574"],"gpt_icon":0},{"id":"2584327965","title":"亚盛医药盘中异动 早盘急速下跌7.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584327965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584327965?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:00","pubTimestamp":1763481637,"startTime":"0","endTime":"0","summary":"北京时间2025年11月19日00时00分，亚盛医药股票出现异动，股价大幅跳水7.00%。截至发稿，该股报30.42美元/股，成交量594股，换手率0.00%，振幅0.52%。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。亚盛医药股票所在的生物技术行业中，整体跌幅为0.33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119000037a70249a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119000037a70249a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139","06855"],"gpt_icon":0},{"id":"2580220496","title":"亚盛医药-B(06855)耐立克®、利生妥®、APG-5918的多项临床进展将在2025年美国血液学会年会(ASH)展示，其中一项获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2580220496","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580220496?lang=zh_cn&edition=full","pubTime":"2025-11-04 08:21","pubTimestamp":1762215703,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司3个品种有多项临床和临床前进展入选第67届美国血液学会年会展示及报告，其中一项获口头报告。此外，公司原创1类新药利沙托克拉共 有 2项临床进展获选第67届ASH年会，其中一项获口头报告。这是该品种的临床进展连续第4年入选 ASH年会。第67届ASH年会将于当地时间2025年12月6 日至12月9日间在美国佛罗里达州奥兰多市以线下结合线上的形式举行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ASH","06855","LU2125909916.SGD","LU2463526074.USD","APG","BK4109","BK4139","BK1574","BK4129","AAPG","LU1923622291.USD","BK1161","LU2125909759.SGD"],"gpt_icon":0},{"id":"2569099557","title":"美联储10月降息概率高达92%，港股医药高位回落","url":"https://stock-news.laohu8.com/highlight/detail?id=2569099557","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569099557?lang=zh_cn&edition=full","pubTime":"2025-09-24 10:11","pubTimestamp":1758679917,"startTime":"0","endTime":"0","summary":"美联储于9月18日如期宣布降息25bp，为港股市场提供了较为宽松的流动性环境。但当前距离10月29日议息尚有35天，美联储相关官员的发言在短期内引起较大扰动。据CME FedWatch Tool数据，美联储10月降息25bp的概率为91.9%；12月降息25bp的概率为21.7%，降息50bp的概率为77%。从二级市场来看，聚焦港股市场创新药+CXO的恒生医药ETF连续调整，自阶段高点回落近6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092410141595415b18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ea3b3b54e2aa42d2aadd6617f904fcb8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092410141595415b18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MESmain","ESmain","SH","BK4588","BK4559","BK4581","OEX","SPXU","AAPG","SSO","09606","UPRO",".SPX","BK4585","IVV","SDS","BK4534","BK4139","SPY","BK4504","OEF","09688","BK4550"],"gpt_icon":0},{"id":"2566698828","title":"每日卖空追踪 | 亚盛医药-B 09月10日卖空量成交12.35万股，卖空比例为5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566698828","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566698828?lang=zh_cn&edition=full","pubTime":"2025-09-10 16:30","pubTimestamp":1757493041,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间09月10日，跌1.68%，卖空量成交12.35万股，较上一交易日减少57.81%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091016350697851d0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091016350697851d0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2564781953","title":"亚盛医药-B09月01日主力净流入1697.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2564781953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564781953?lang=zh_cn&edition=full","pubTime":"2025-09-01 16:15","pubTimestamp":1756714535,"startTime":"0","endTime":"0","summary":"09月01日, 亚盛医药-B股价涨0.12%，报收83.25元，成交金额2.4亿元，换手率0.78%，振幅2.77%，量比0.59。亚盛医药-B今日主力资金净流入1697.0万元，上一交易日主力净流出815.6万元。该股近5个交易日下跌3.42%，主力资金累计净流出1557.3万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入5220.1万元，其中净流入天数为8日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901170942a7090fba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901170942a7090fba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2562291249","title":"港股生物医药股震荡回调，欧康维视生物跌超15%，百奥赛图、中国抗体跌超8.5%，亚盛医药跌超6%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562291249","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562291249?lang=zh_cn&edition=full","pubTime":"2025-08-25 10:51","pubTimestamp":1756090312,"startTime":"0","endTime":"0","summary":"港股生物医药股震荡回调，欧康维视生物跌超15%，百奥赛图、中国抗体跌超8.5%，亚盛医药跌超6%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/25105152660744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HSTECH","BK1161","03681","BK1574","161726","HSCEI","399441","BK4614","AAPG","07226","BK4139","YANG"],"gpt_icon":0},{"id":"2562291614","title":"中金：维持亚盛医药-B(06855)跑赢行业评级 升目标价至105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562291614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562291614?lang=zh_cn&edition=full","pubTime":"2025-08-25 10:39","pubTimestamp":1756089589,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持亚盛医药-B2025年/2026年归母净利润预测不变，维持跑赢行业评级，考虑到GLORA-4进展，新适应症空间可见度提升，根据DCF模型，上调目标价19.3%至105港币，离当前股价有15.8%的上行空间。公司1H25收入2.34亿元，主要由于去年同期产生授权收入，1H25业绩符合该行预期。该行认为MDS患者人群广泛，一线治疗存在较大未满足需求，公司利生妥这一布局有望加码其差异化优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG"],"gpt_icon":0},{"id":"2561147611","title":"每日卖空追踪 | 亚盛医药-B 08月22日卖空量成交17万股，卖空比例为5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561147611","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561147611?lang=zh_cn&edition=full","pubTime":"2025-08-22 16:30","pubTimestamp":1755851437,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间08月22日，涨0.5%，卖空量成交17万股%，较上一交易日减少39.2%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822174123a4983e1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822174123a4983e1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2561476199","title":"亚盛医药-B08月22日获主力加仓1782.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2561476199","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561476199?lang=zh_cn&edition=full","pubTime":"2025-08-22 16:15","pubTimestamp":1755850533,"startTime":"0","endTime":"0","summary":"08月22日, 亚盛医药-B股价涨0.50%，报收90.65元，成交金额2.8亿元，换手率0.82%，振幅3.82%，量比0.68。亚盛医药-B今日主力资金净流入1782.2万元，上一交易日主力净流入1179.5万元。该股近5个交易日上涨5.05%，主力资金累计净流出1001.0万元；近20日主力资金累计净流入6971.9万元，其中净流入天数为9日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822170525a6f52b47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822170525a6f52b47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentage.com","stockEarnings":[{"period":"1week","weight":-0.0883},{"period":"1month","weight":-0.1153},{"period":"3month","weight":-0.2911},{"period":"6month","weight":-0.455},{"period":"1year","weight":0.2819},{"period":"ytd","weight":-0.1109}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤治疗药物发现、研发及商业化的控股公司。该公司主营业务是从事开发及销售针对肿瘤、乙肝及老化相关的疾病的新型小规模疗法。该公司的主要产品包括Olverembatinib（HQP1351）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918等产品。该公司的产品主要用于治疗主要血液系统恶性肿瘤，包括慢性粒细胞白血病、急性粒细胞白血病、慢性淋巴细胞白血病、急性淋巴细胞白血病、骨髓增生异常综合症及多发性骨髓瘤。该公司主要在国内市场开展业务。","exchange":"NASDAQ","name":"亚盛医药","nameEN":"ASCENTAGE PHARMA GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,AAPG,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}